Artemisinin Concept Stocks Lead Gains with 3.7% Rise; Three Shares Hit Daily Limit
Artemisinin concept stocks rose 3.7% at the close on August 12, leading all concept sectors. Eight stocks in the sector advanced, with Baihua Medicine, Delong Hui Neng, and Zhejiang Medicine hitting the daily limit. Main capital saw a net inflow of RMB 348 million into the sector, led by Zhejiang Medicine with RMB 254 million.
As of the close on August 12, the artemisinin concept sector rose 3.7%, ranking first among concept sectors in terms of gains. Eight stocks in the sector advanced, with Baihua Medicine, Delong Hui Neng, and Zhejiang Medicine hitting the daily limit. Kunming Pharma, Hisun Pharmaceutical, and Rundo Pharma rose 3.98%, 1.66%, and 0.96%, respectively. On the downside, Fosun Pharma fell 0.33%, and Baiyunshan fell 0.19%.
Among the day's top-gaining concept sectors, the home rental rights sector rose 3.58%, optical fiber concept rose 3.29%, co-packaged optics (CPO) rose 2.98%, Hengqin New Area and F5G concepts each rose 2.71%, hyperbaric oxygen chamber rose 2.56%, characteristic towns rose 2.53%, high-speed copper cable connection rose 2.45%, and property management rose 2.45%. On the losing side, fentanyl fell 0.93%, combustible ice fell 0.9%, recombinant protein fell 0.39%, shale gas fell 0.15%, cellular immunotherapy fell 0.08%, chicken farming fell 0.01%, Russia-Ukraine conflict concept fell 0.01%, titanium dioxide concept rose 0.02%, cross-border payment (CIPS) rose 0.04%, and MLOps concept rose 0.1%.
In terms of capital flows, the artemisinin concept sector recorded a net main capital inflow of RMB 348 million on the day, with four stocks seeing net inflows. Zhejiang Medicine led with a net main capital inflow of RMB 254 million; Delong Hui Neng saw RMB 112 million, NHU saw RMB 56.4466 million, and Kunming Pharma saw RMB 14.2028 million. In terms of capital inflow ratios, the net main capital inflow rates for Zhejiang Medicine, Delong Hui Neng, and NHU were 27.92%, 25.67%, and 5.42%, respectively.